Literature DB >> 15354868

Genetic studies in relation to kuru: an overview.

L G Goldfarb1, L Cervenakova, D C Gajdusek.   

Abstract

Kuru is a subacute neurodegenerative disease presenting with limb ataxia, dysarthria, and a shivering tremor. The disease progress to complete motor and mental incapacity and death within 6 to 24 months. Neuropathologically, a typical pattern of neuronal loss, astrocytic and microglial proliferation, characteristic "kuru-type" amyloid plaques, and PrP deposits in the cerebral cortex and cerebellum are observed. Kuru is the prototype of a group of human transmissible spongiform encephalopathies (TSEs), or "prion" diseases, that include hereditary, sporadic and infectious forms. The latest member of this group, the variant Creutzfeldt-Jakob disease (vCJD), linked to transmission of bovine spongiform encephalopathy (BSE) to humans, shows features similar to kuru. Kuru has emerged at the beginning of the 1900s in a small indigenous population of New-Guinean Eastern Highlands, reached epidemic proportions in the mid-1950s and disappeared progressively in the latter half of the century to complete absence at the end of the 1990s. Early studies made infection, the first etiologic assumption, seem unlikely and led to a hypothesis that kuru might be a genetically determined or genetically mediated illness. After transmissibility of kuru had been discovered and all major epidemiologic phenomena adequately explained by the spread of an infectious agent with long incubation period through the practice of cannibalism, the pattern of occurrence still continued to suggest a role for genetic predisposition. Recent studies indicate that individuals homozygous for Methionine at a polymorphic position 129 of the prion protein were preferentially affected during the kuru epidemic. The carriers of the alternative 129Met/Val and 129Val/Val genotypes had a longer incubation period and thus developed disease at a later age and at a later stage of the epidemic. Observations made during the kuru epidemic are helpful in the understanding of the current vCJD outbreak, and vice versa clinical and experimental data accumulated in studies of other TSE disorders contribute to better understanding of the documented kuru phenomena.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15354868     DOI: 10.2174/1566524043360627

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  6 in total

Review 1.  Quantum dots and prion proteins: is this a new challenge for neurodegenerative diseases imaging?

Authors:  Pavlina Sobrova; Iva Blazkova; Jana Chomoucka; Jana Drbohlavova; Marketa Vaculovicova; Pavel Kopel; Jaromir Hubalek; Rene Kizek; Vojtech Adam
Journal:  Prion       Date:  2013-09-20       Impact factor: 3.931

Review 2.  Kuru: genes, cannibals and neuropathology.

Authors:  Pawel P Liberski; Beata Sikorska; Shirley Lindenbaum; Lev G Goldfarb; Catriona McLean; Johannes A Hainfellner; Paul Brown
Journal:  J Neuropathol Exp Neurol       Date:  2012-02       Impact factor: 3.685

3.  Variant Creutzfeldt-Jakob disease: prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study.

Authors:  James W Ironside; Matthew T Bishop; Kelly Connolly; Doha Hegazy; Suzanne Lowrie; Margaret Le Grice; Diane L Ritchie; Linda M McCardle; David A Hilton
Journal:  BMJ       Date:  2006-04-10

Review 4.  Kuru: a journey back in time from papua new Guinea to the neanderthals' extinction.

Authors:  Pawel P Liberski
Journal:  Pathogens       Date:  2013-07-18

Review 5.  Kuru, the First Human Prion Disease.

Authors:  Paweł P Liberski; Agata Gajos; Beata Sikorska; Shirley Lindenbaum
Journal:  Viruses       Date:  2019-03-07       Impact factor: 5.048

6.  Mother to offspring transmission of chronic wasting disease in reeves' muntjac deer.

Authors:  Amy V Nalls; Erin McNulty; Jenny Powers; Davis M Seelig; Clare Hoover; Nicholas J Haley; Jeanette Hayes-Klug; Kelly Anderson; Paula Stewart; Wilfred Goldmann; Edward A Hoover; Candace K Mathiason
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.